GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Nexalin Technology Inc.
Nexalin is a medical company developing a non-invasive brain stimulation device for the treatment of mental disorders. Its stock price is a venture bet on this technology. The chart reflects high volatility and dependence on news about clinical trials.
Share prices of companies in the market segment - Psycho
Nexalin Technology has developed a non-invasive neurostimulation device designed to treat anxiety disorders, depression, and insomnia. We've categorized it as "Psycho." The chart below shows how the market is evaluating new mental health technologies.
Broad Market Index - GURU.Markets
Nexalin is a medical device company that has developed a non-invasive neurostimulation device for the treatment of mental disorders. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Nexalin's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
NXL - Daily change in the company's share price Nexalin Technology Inc.
Nexalin Technology, Inc.'s daily stock price fluctuations reflect the high volatility inherent in companies developing medical devices for the treatment of mental disorders. This metric is a measure of sensitivity to clinical trial data.
Daily change in the price of a set of shares in a market segment - Psycho
Nexalin Technology, Inc. is a medical technology company. This chart illustrates the high volatility of the MedTech industry. Comparing it to NXL, which focuses on neurostimulation, helps us understand how its innovative products contribute to its volatility.
Daily change in the price of a broad market stock, index - GURU.Markets
Nexalin Technology develops non-invasive devices for the treatment of mental disorders. Shares of this innovative medtech company are responding to clinical advances and regulatory decisions, contributing to the overall volatility of the healthcare sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Nexalin Technology Inc.
Nexalin Technology, Inc.'s year-over-year performance is a story about the commercialization of its non-invasive device for treating anxiety, depression, and insomnia. Its 12-month market cap depends entirely on progress in obtaining regulatory approvals and convincing doctors and patients of the effectiveness of its neurostimulation therapy.
Annual dynamics of market capitalization of the market segment - Psycho
Nexalin, a company developing non-invasive therapies for mental disorders, is a bet on medical innovation. Its performance relative to the sector will reveal how much investors believe in its ability to commercialize its unique technology and secure regulatory approval.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nexalin Technology, with its device for treating mental disorders, is trying to carve out a niche in medical technology. Its year-over-year performance reflects expectations of clinical and commercial acceptance. Market comparisons demonstrate investors' confidence in the potential of non-drug treatments and the company's ability to bring the product to market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Nexalin Technology Inc.
Nexalin Technology develops neurostimulation devices. Being in the commercialization stage, its monthly valuation depends on progress toward FDA approval and initial sales. Updates on clinical data and regulatory approvals are key.
Monthly dynamics of market capitalization of the market segment - Psycho
Nexalin Technology has developed a non-invasive neurostimulation device designed to treat anxiety, depression, and insomnia. The technology uses electrical fields to stimulate the brain. The graph below shows the dynamics of the medical device sector, where the search for non-drug treatments for mental disorders is a major trend.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nexalin Technology is developing a non-invasive device for treating mental disorders. It's a medical startup whose value is based on the potential of its technology. Its shares are driven by news of clinical trials and regulatory approvals, completely ignoring overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Nexalin Technology Inc.
Nexalin Technology develops non-invasive neurostimulation devices for the treatment of mental disorders. Its weekly stock price is volatile and depends on clinical trial results and regulatory approvals.
Weekly dynamics of market capitalization of the market segment - Psycho
Nexalin Technology offers therapy for mental disorders. Shares of such companies are highly sensitive to news. The chart shows whether weekly fluctuations reflect unique data on the therapy's effectiveness or general investor sentiment in the neuroscience sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Nexalin Technology, as a medical technology company, should be less dependent on economic cycles. The chart will show how insulated the company's shares are from general market fluctuations, moving with product news and regulatory decisions while ignoring macroeconomic noise.
Market capitalization of the company, segment and market as a whole
NXL - Market capitalization of the company Nexalin Technology Inc.
Nexalin Technology's stock price is a bet on non-invasive neurostimulation. Its market cap reflects investors' faith in the company's potential for treating anxiety, depression, and insomnia. This is a highly volatile curve, typical for medtech companies in the early stages of commercialization.
NXL - Share of the company's market capitalization Nexalin Technology Inc. within the market segment - Psycho
Nexalin Technology has developed a non-invasive neurostimulation device for the treatment of anxiety, depression, and insomnia. Its market capitalization in the psychotherapy equipment segment reflects the potential of this new technology. The company's market share reflects the company's bet that its method will become a safe and effective alternative to drug-based treatment for mental disorders.
Market capitalization of the market segment - Psycho
Nexalin Technology has developed a non-invasive device for treating anxiety and insomnia. What is the scale of this problem? The graph below shows the overall market capitalization of the psychotherapy sector. Its growth reflects the enormous need for new, non-drug treatments for mental disorders.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Nexalin Technology chart shows how the market values a non-invasive technology for treating mental disorders. The company's market cap is based on its brain-stimulating devices for anxiety and insomnia. This chart shows a venture bet on a new approach to neurostimulation.
Book value capitalization of the company, segment and market as a whole
NXL - Book value capitalization of the company Nexalin Technology Inc.
Nexalin Technology's assets include its production lines for creating neurostimulation devices for treating mental disorders, as well as its R&D infrastructure. Its book value reflects the value of these high-tech medical assets. The chart below shows how the company has invested its capital.
NXL - Share of the company's book capitalization Nexalin Technology Inc. within the market segment - Psycho
Nexalin Technology, Inc. creates non-invasive devices for the treatment of mental disorders. Its tangible assets include production lines for assembling its neurostimulation devices and an R&D laboratory. The chart shows the company's control over this innovative medical manufacturing infrastructure in the field of neurotechnology.
Market segment balance sheet capitalization - Psycho
Nexalin Technology is a medical technology company. This sector, as the chart shows, is capital-intensive. Nexalin has developed a unique neurostimulation device, and its capital is invested in the R&D and production of this complex device.
Book value of all companies included in the broad market index - GURU.Markets
Nexalin's assets are not drugs, but rather manufacturing facilities for creating neurostimulation devices that generate waveforms for the treatment of anxiety, depression, and insomnia. Its book value reflects its industrial and technological potential in the field of non-invasive brain therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Nexalin Technology Inc.
Nexalin is developing a non-invasive brain stimulation device for the treatment of mental disorders. The company has no tangible assets. Its market capitalization is a bet on its technology and its ability to gain FDA approval. The chart illustrates the risks and potential of this new approach to treating brain disorders.
Market to book capitalization ratio in a market segment - Psycho
Nexalin Technology has developed a non-invasive device for the treatment of anxiety, depression, and insomnia. This is a medical technology where patents and clinical data are everything. The chart shows how the market values its scientific breakthrough and commercial potential compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
Nexalin Technology develops devices for the treatment of mental disorders. Patents for the technology and its potential applications are key valuation drivers, not physical assets. This chart shows the high premium investors place on innovative medical technologies targeting large and underserved markets.
Debts of the company, segment and market as a whole
NXL - Company debts Nexalin Technology Inc.
Nexalin Technology is developing a medical device for treating mental disorders using neurostimulation. Bringing a new medical device to market is a lengthy and expensive process, requiring clinical trials and approvals. This chart shows how the company is funding its efforts to commercialize this innovative, but not yet mass-market, technology.
Market segment debts - Psycho
Nexalin Technology is developing a medical device for non-invasive brain stimulation to treat mental disorders. While in the commercialization stage, the company incurs significant costs for approvals, marketing, and sales. This chart shows how it finances this complex and expensive process of bringing an innovative product to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Nexalin Technology Inc.
Nexalin Technology develops devices for the treatment of neuropsychiatric disorders. This chart shows its financial structure. For a company whose product is based on new technology and requires medical acceptance, debt is a significant risk. Success depends on commercialization, and the company may not have the revenue to service the debt.
Market segment debt to market segment book capitalization - Psycho
Nexalin Technology develops non-invasive neurostimulation devices for the treatment of mental disorders. This is an innovative field, but one that requires clinical proof. The chart shows the overall debt burden in the medical device sector, providing context for assessing how the company finances its expensive research and development.
Debt to book value of all companies in the market
Nexalin Technology is developing a medical device for treating mental disorders using electrical stimulation. The company incurs significant costs during the product's commercialization phase. This chart shows general financing terms, helping to understand the financing options—debt or equity—available to Nexalin for the commercialization of its technology.
P/E of the company, segment and market as a whole
P/E - Nexalin Technology Inc.
This chart shows the valuation of Nexalin Technology, a company developing devices for treating mental disorders. The price-to-earnings ratio (if any) will be based on investors' faith in its non-invasive technology. This is a bet that its device can become an effective and safe alternative to medication.
P/E of the market segment - Psycho
Nexalin Technology is a medical device company that has developed a non-invasive neurostimulation device for the treatment of anxiety, depression, and insomnia. This chart shows the average rating for the psychotherapy sector, helping to understand how the market views this innovative mental health technology.
P/E of the market as a whole
Nexalin Technology is developing a medical device that uses neurostimulation to treat mental disorders. Its valuation is a pure bet on the success of this innovative technology. It is not tied to the general economic cycles illustrated by this chart. Its fate is decided in clinics and depends on regulatory approval.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Nexalin Technology Inc.
Nexalin Technology is developing a medical device for non-invasive deep brain stimulation to treat mental disorders such as anxiety and insomnia. This chart reflects investor expectations for clinical trials and regulatory approvals. The valuation is based on the potential for a breakthrough in neurostimulation.
%20P%2FE%20Nexalin%20Technology%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Nexalin-Technology-Inc.&v=1772619133055 "Chart of the company's future (projected) P/E Nexalin Technology Inc.")
Future (projected) P/E of the market segment - Psycho
Nexalin Technology is developing a medical device for treating anxiety, depression, and insomnia using neurostimulation. Its valuation, relative to other companies in the mental health sector, reflects the expectations of its non-invasive technology. This is a bet by investors that its approach will become a sought-after alternative to drug treatment.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Psycho&v=1772619133097 "Future (projected) P/E graph of the market segment - Psycho")
Future (projected) P/E of the market as a whole
Nexalin Technology is developing a medical device for non-invasive brain stimulation to treat mental disorders such as anxiety and insomnia. The company's success depends on regulatory approval and the acceptance of the technology by doctors. This chart reflects the overall risk appetite of investors, which is important for evaluating companies bringing fundamentally new medical technologies to market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772619133111 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Nexalin Technology Inc.
Nexalin Technology has developed a non-invasive neurostimulation device for the treatment of anxiety, depression, and insomnia. The financial results illustrated in this chart reflect its progress toward commercializing this new technology. Regulatory approvals and medical acceptance are key to success.
Profit of companies in the market segment - Psycho
Nexalin Technology is developing a medical device for non-invasive brain stimulation to treat mental disorders. This chart shows the financial status of the psychological and neurological care sector. It demonstrates the market and medical community's readiness to embrace new, non-drug therapies.
Overall market profit
Nexalin Technology is developing a medical device for non-invasive brain stimulation to treat mental disorders. This is an innovative field of medicine. The company's success depends on regulatory approvals and recognition from the medical community, not on economic cycles, as this chart illustrates.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Nexalin Technology Inc.
Nexalin Technology is developing a medical device for non-invasive brain stimulation designed to treat mental disorders. The company's future profitability depends on regulatory approval and medical acceptance of this technology. This chart shows analysts' assessments of the commercialization prospects of this innovative treatment method.
%20profit%20of%20the%20company%20Nexalin%20Technology%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Nexalin-Technology-Inc.&v=1772619133395 "Graph of future (projected) profit of the company Nexalin Technology Inc.")
Future (predicted) profit of companies in the market segment - Psycho
Nexalin Technology has developed a non-invasive neurostimulation device designed to treat anxiety, depression, and insomnia. The technology aims to normalize brain neurochemistry. This graph shows forecasts for the psychoneurological sector, illustrating the potential of new, non-drug methods to address this growing mental health problem.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Psycho&v=1772619133523 "Graph of future (predicted) profits of companies in a market segment - Psycho")
Future (predicted) profit of the market as a whole
This graph reflects the overall economic situation, which impacts healthcare budgets and capital availability. For Nexalin Technology, which develops neurostimulation devices, this determines the speed of adoption of their technologies. A growing economy allows clinics to invest in new equipment, while a recession forces them to postpone purchases.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772619133555 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Nexalin Technology Inc.
Nexalin Technology has developed a non-invasive device for treating mental disorders. This figure reflects investors' assessment of its early revenue and the huge potential market. It's a bet that its technology will revolutionize neurostimulation.
P/S market segment - Psycho
Nexalin Technology is developing a non-invasive neurostimulation device for the treatment of central nervous system disorders such as anxiety and insomnia. This chart shows the average valuation in the psychotherapy sector, reflecting investor expectations for new, non-drug approaches to treating mental disorders.
P/S of the market as a whole
Nexalin Technology, Inc. develops non-invasive neurostimulation devices for the treatment of anxiety, depression, and insomnia. The company's future revenue is dependent on regulatory approvals and commercial launch. This chart provides a general framework for assessing how the market values medical technologies in the development stage.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Nexalin Technology Inc.
Nexalin Technology is developing a non-invasive neurostimulation device for the treatment of mental disorders. The company's future revenue is entirely dependent on FDA approval and successful market launch. This chart demonstrates investors' confidence in the potential of this new technology for treating anxiety and insomnia.
%20P%2FS%20Nexalin%20Technology%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Nexalin-Technology-Inc.&v=1772619133729 "The graph of the company's future (projected) P/S Nexalin Technology Inc.")
Future (projected) P/S of the market segment - Psycho
Nexalin Technology has developed a non-invasive neurostimulation device designed to treat anxiety, depression, and insomnia by targeting specific areas of the brain. This chart shows how investors assess the commercial potential of this new mental health technology compared to other medical companies.
%20P%2FS%20market%20segment%20graph%20-%20Psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Psycho&v=1772619133767 "Future (projected) P/S market segment graph - Psycho")
Future (projected) P/S of the market as a whole
This indicator summarizes expectations for the medical technology market. For Nexalin Technology, a developer of a non-invasive brain stimulation device for treating mental disorders, it is an indicator of innovation adoption. Market optimism helps fund the implementation of new therapies that could become alternatives to traditional medications.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772619133829 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Nexalin Technology Inc.
Nexalin Technology has developed a non-invasive neurostimulation device designed to treat anxiety, depression, and insomnia. This chart will reflect revenue from sales of these devices to clinics and medical centers. Increased sales will indicate the acceptance of this new therapeutic modality by doctors and patients as an alternative to medication.
Sales of companies in the market segment - Psycho
Nexalin Technology is developing a non-invasive neurostimulation device designed to treat anxiety disorders, depression, and insomnia. This graph illustrates the growth in the psychotherapy technology sector. Nexalin offers an alternative to drug treatment, which is part of a broader trend toward new approaches in psychiatry.
Overall market sales
Nexalin Technology, Inc. develops medical devices for the treatment of neuropsychiatric disorders using non-invasive brain stimulation. Demand for its technology depends on its implementation in clinical practice. The overall economic environment, shown in this graph, influences healthcare budgets and their willingness to adopt new treatment methods.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Nexalin Technology Inc.
Nexalin Technology is developing a non-invasive neurostimulation device designed to treat anxiety, depression, and insomnia. The company's future revenue is dependent on FDA approval and clinical implementation of this technology. This graph reflects analyst expectations regarding the commercial potential of this new approach to treating mental disorders.
%20sales%20of%20the%20company%20Nexalin%20Technology%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Nexalin-Technology-Inc.&v=1772619133957 "Schedule of future (projected) sales of the company Nexalin Technology Inc.")
Future (projected) sales of companies in the market segment - Psycho
Nexalin Technology has developed a non-invasive neurostimulation device designed to treat mental disorders. This graph reflects expectations for the psychotherapy equipment sector, demonstrating growing interest in alternative, non-drug treatments for mental illnesses.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Psycho&v=1772619133996 "Schedule of future (projected) sales of companies in the market segment - Psycho")
Future (projected) sales of the market as a whole
Nexalin Technology, Inc. develops and commercializes non-invasive neurostimulation devices for the treatment of mental disorders. The company's success depends on the acceptance of its technology by the medical community. This graph, reflecting the overall economic situation, influences clinics' willingness to invest in new equipment and the availability of such treatments for patients.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772619134001 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Nexalin Technology Inc.
Nexalin Technology has developed a non-invasive device for treating anxiety and insomnia using neurostimulation. This chart shows the financial outlook at the product launch stage. Future profitability will depend on regulatory approval, acceptance by the medical community, and reimbursement from insurance companies.
Market segment marginality - Psycho
Nexalin Technology develops non-invasive devices for the treatment of anxiety, depression, and insomnia. For a medical technology company, profitability depends on the effectiveness and acceptance of their method. This chart shows the average profitability in the industry, allowing one to estimate the commercial potential of Nexalin's technology if it is widely adopted.
Market marginality as a whole
Nexalin Technology is developing a non-invasive device for the treatment of anxiety, depression, and insomnia. This overall market revenue graph does not directly impact the company. Demand for its technology is driven by growing needs in the mental health field. Its success depends on clinical evidence of effectiveness and acceptance by the medical community.
Employees in the company, segment and market as a whole
Number of employees in the company Nexalin Technology Inc.
Nexalin Technology is developing a medical device for non-invasive brain stimulation to treat mental disorders. This graph shows a small team focused on clinical trials and regulatory approval. Growing the team will signal the company's transition to commercialization.
Share of the company's employees Nexalin Technology Inc. within the market segment - Psycho
Nexalin Technology has developed a non-invasive neurostimulation device for the treatment of mental disorders. This chart shows the percentage of biomedical engineers and clinicians specializing in neuromodulation that the company attracts. It reflects its unique focus on creating breakthrough technologies in mental health.
Number of employees in the market segment - Psycho
Nexalin Technology has developed a non-invasive neurostimulation device designed to treat mental disorders such as anxiety and insomnia. This graph illustrates how new treatment approaches are emerging at the intersection of medicine and electronics, requiring the involvement of neuroscientists, engineers, and clinical specialists to implement them.
Number of employees in the market as a whole
Nexalin Technology develops devices for the treatment of neuropsychiatric disorders. This is an example of how technology is penetrating the most complex areas of medicine. The overall employment picture shown in this graph includes the growing MedTech sector, where innovators like Nexalin are creating demand for engineers, doctors, and new research professionals.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Nexalin Technology Inc. (NXL)
Nexalin Technology develops medical devices for neurostimulation (CNS treatment). This chart reflects the high value of its intellectual capital. The company's main asset is its patented technology and devices in clinical trials and commercialization. The chart shows how highly the market values this unique medical IP per engineer.
%20of%20the%20company%20Nexalin%20Technology%20Inc.%20(NXL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Nexalin-Technology-Inc.-NXL&v=1772619134489 "Chart of market capitalization per employee (in thousands of dollars) of the company Nexalin Technology Inc. (NXL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Psycho
Nexalin Technology develops neurostimulation devices for the treatment of mental disorders. This is an innovative field where value is determined by the technology's potential. The chart shows how investors are betting on the company's scientific and engineering team. A comparison with the medical technology sector allows one to appreciate the uniqueness and potential of their approach.
%20by%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Psycho&v=1772619134507 "Market capitalization per employee (in thousands of dollars) by market segment - Psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Nexalin Technology has developed a non-invasive device for the treatment of neuropsychiatric disorders. This graph shows the average market value of one employee's contribution. It illustrates how the market evaluates the potential of innovative medical technologies.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772619134524 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Nexalin Technology Inc. (NXL)
Nexalin Technology is developing a medical device for neurostimulation (for the treatment of anxiety and depression). The company is in the early stages of commercialization. This graph likely represents the loss per employee. It reflects the investment in R&D and marketing required to bring a new medical device to market.
%20Chart%20Nexalin%20Technology%20Inc.%20(NXL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Nexalin-Technology-Inc.-NXL&v=1772619134550 "Company Profit Per Employee (in thousands of dollars) Chart Nexalin Technology Inc. (NXL)")
Profit per employee (in thousands of dollars) in the market segment - Psycho
Nexalin Technology develops a medical device for non-invasive brain stimulation to treat mental disorders. This is a knowledge-intensive business, requiring a team of engineers and clinical research specialists. This graph shows the financial return per employee, which for companies at the commercialization stage is an indicator of market acceptance of their innovative technology.
%20in%20the%20market%20segment%20-%20Psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Psycho&v=1772619134584 "Chart of profit per employee (in thousands of dollars) in the market segment - Psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Nexalin Technology (NXL) is a MedTech company that has developed a non-invasive neurostimulation device that they claim treats anxiety, depression, and insomnia. This R&D and commercialization of medical devices is underway. This chart serves as a general economic benchmark. It helps assess how effective NXL's IP-based MedTech model is in generating revenue per capita.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772619134601 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Nexalin Technology Inc. (NXL)
Nexalin Technology is developing a medical device for treating mental disorders using neurostimulation. This graph shows the path from development to market. Growth in this indicator will indicate the successful implementation of the technology into clinical practice and the company's ability to generate revenue for its team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Nexalin-Technology-Inc.-NXL&v=1772619134658 "Sales chart per company employee Nexalin Technology Inc. (NXL)")
Sales per employee in the market segment - Psycho
Nexalin Technology develops medical devices for non-invasive brain stimulation to treat mental disorders (anxiety, insomnia). It's a medtech company. This chart shows the average revenue per employee in the segment. It helps evaluate how effectively the Nexalin team is commercializing its technology compared to its competitors.
Sales per employee for the market as a whole
Nexalin Technology develops a medical device that uses non-invasive brain stimulation to treat mental disorders (anxiety, depression). This graph shows how effectively their team (engineers, clinicians, and salespeople) generates revenue from the sale or lease of their innovative medical equipment.
Short shares by company, segment and market as a whole
Shares shorted by company Nexalin Technology Inc. (NXL)
Nexalin Technology is promoting a medical neurostimulation device that they claim treats anxiety, depression, and insomnia. This is a highly speculative technology with no broad evidence base. This chart shows the bets that it will be a dud. The bears are confident the company will fail to secure FDA approval or convince doctors of its effectiveness.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Nexalin-Technology-Inc.-NXL&v=1772619134807 "Short Shares Chart for the Company Nexalin Technology Inc. (NXL)")
Shares shorted by market segment - Psycho
Nexalin Technology, Inc. is developing a medical device using non-invasive brain stimulation (deep brain stimulation) to treat mental disorders such as anxiety and insomnia. This chart shows the aggregate short position in the neuropsychiatric services and equipment sector. Its rise may reflect investor concerns about the difficulty of obtaining FDA approval for such devices.
Shares shorted by the overall market
Nexalin is a company promoting a neurostimulation device (for the treatment of anxiety and depression). This chart illustrates the overall market pessimism. Investors are skeptical of new methods in psychiatry. In times of fear, they are unwilling to take risks, fearing the technology will not gain approval and acceptance.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Nexalin Technology Inc. (NXL)
This oscillator for Nexalin is a barometer of faith in non-invasive brain stimulation. The company promotes its device for treating anxiety, depression, and insomnia using weak electrical currents. "Overheating" (above 70) occurs due to positive research data or regulatory news. Skepticism from the scientific community and slow adoption keep the stock "oversold."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Nexalin-Technology-Inc.-NXL&v=1772619134847 "RSI 14 indicator chart for the company's stock Nexalin Technology Inc. (NXL)")
RSI 14 Market Segment - Psycho
Nexalin (NXL) is "electro-sleep." Their device (Gen-2) is a non-invasive deep transcranial neurostimulation (DTNS) treatment for insomnia and anxiety. The "Psycho" (medtech/neuro) sector thrives on hype. RSI_14_Seg shows the "temperature" of the entire industry. It helps us understand: is NXL's growth a niche product or a product of the general hype?
RSI 14 for the overall market
Nexalin (NXL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NXL (Nexalin Technology Inc.)
Nexalin Technology is developing a non-invasive neurostimulation device designed to treat mental disorders such as anxiety and depression. This chart shows the analysts' average 12-month forecast, representing their collective bet on whether this technology will receive FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NXL-Nexalin-Technology-Inc.&v=1772619134995 "A chart showing analyst consensus forecasts for the expected stock price. NXL (Nexalin Technology Inc.)")
The difference between the consensus estimate and the actual stock price NXL (Nexalin Technology Inc.)
Nexalin is a medical technology company developing a non-invasive neurostimulation (tACS) device designed to treat anxiety, depression, and insomnia. This chart shows how far the current stock price differs from the "fair" value predicted by analysts. It reflects their confidence in FDA approval and commercialization of this technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NXL-Nexalin-Technology-Inc.&v=1772619135032 "A chart showing the difference between the consensus forecast and the actual stock price. NXL (Nexalin Technology Inc.)")
Analyst consensus forecast for stock prices by market segment - Psycho
Nexalin is a MedTech company developing a non-invasive brain stimulation device (neurostimulation) for the treatment of depression and anxiety. This chart reflects analyst expectations across the entire psychopharma and MedTech sector. It shows whether experts believe in hardware-based solutions for the central nervous system.
Analysts' consensus forecast for the overall market share price
Nexalin Technology is a company developing a medical device for non-invasive brain stimulation (NBS) designed to treat anxiety, depression, and insomnia. This technology is in its early stages. This chart reflects the overall market "risk appetite." For Nexalin, whose value is an option on the success of their device, overall market optimism (risk appetite) is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Nexalin Technology Inc.
Nexalin is a MedTech company working in psycho-technology. Their signature device is a non-invasive device (a neurostimulator) that uses electrical impulses to treat anxiety, depression, and insomnia. This chart is a clear indicator of their R&D. It reflects their (very risky) path to FDA approval and their (still) speculative bet on electrical psychiatry.
AKIMA Market Segment Index - Psycho
Nexalin Technology (NXL) is developing a non-invasive neurostimulation device. Their technology (deep stimulation) is designed to treat anxiety, depression, and insomnia without the use of medications. The chart shows the average index for the segment, helping investors assess how the risks and potential of this drug-free psychotherapy compare to the average.
The AKIM Index for the overall market
Nexalin Technology is a company developing non-invasive neurostimulators for the drug-free treatment of mental disorders (anxiety, insomnia). This chart, which reflects the market average, is a backdrop. It helps assess how this alternative medical technology compares to overall macroeconomic trends.
